TBA

Kate Oliver is the Senior Manager for Clinical Trials at Cellectar Biosciences, Inc. bringing more than 20 years of clinical research experience. Previously, she was a Program Manager for an early phase oncology group at a large academic institution, managing study start up and program activities. At Cellectar, Ms Oliver has played a significant role in clinical operations, trial development, and oversight of CROs. She feels that a patient-centric approach to execution of clinical trials is a pathway to success.

Stacey Langley is a devoted advocate for patient rights and improved healthcare experiences. With a background as a community health worker and peer recovery specialist, she brings a unique perspective on patient advocacy.

Having personally navigated physical disability, autoimmune disease, behavioral health, and recovery, Ms Langley understands the significance of empowering individuals to become active participants in their healthcare journey. She firmly believes that every patient deserves a voice and that collective advocacy can drive meaningful change.

For over a decade, Ms Langley has been an active participant in various campaigns in the LGBTQ+, progressive, and low-income communities, all aimed to improve patient outcomes, amplify patient voices, and address systemic issues in healthcare.

Beyond her advocacy work, Ms Langley is also a sought-after speaker known for inspiring and educating diverse audiences. Originally from Houston, Texas, and having spent over a decade in the New York City area, she currently resides near Martinsburg, West Virginia. Ms Langley holds an AAS in Information Systems from Pierpont Community and Technical College and a certificate in Community Health from Berkeley City College.

TBA

Emily Idoni is a Senior Account Director in Langland’s US office. In her almost six years at Langland, she has gone from successfully delivering master materials and translations, to leading best-in-class creative work, and now, to leading the team to strategically deliver on each project’s specific needs and KPIs. Whether oncology, women’s health, or rare disease, she is inspired by the possibility of touching patients’ and caregivers’ journeys and giving each stakeholder the best possible experience while they engage with clinical research.

Before joining Langland, Emily worked in a small, nimble agency that specialized in brand development and digital ecosystem, which she uses extensively when co-creating clinical studies’ brands.  From working on a variety of brands in a variety of industries, like specialty pharmacy, nonprofits, and manufacturing, she is acutely aware of the importance of a consistent brand and message and looks to provide this consistency to clinical research participants whenever possible.

Throughout her time at Langland, Emily has led a variety of projects ranging from study brand development to full study support including digital recruitment. She has worked on more than 20 therapies and delivered materials in over 35 languages. Because of this breadth of experience, she is able to share insights and recommendations, all while working to be the best possible steward of any budget.  

Arun Balakumaran, MD, Ph.D., is Replay's Chief Medical Officer. With a proven track record of leading teams and an innate ability to prioritize and solve complex challenges, Arun consistently delivers outstanding results. As an MD, Ph.D., and board-certified specialist in Hematology and Medical Oncology, Arun combines his extensive medical knowledge with a Master's in Healthcare Management. His passion for immune therapies and cell and gene therapy has guided his career from laboratory research to clinical development across phases 1 to 4. Arun has demonstrated exceptional leadership throughout his journey, securing breakthrough designations and overseeing successful registration experiences. Most recently, he was the CMO of Allogene, where he led the programs to a pivotal stage in heme malignancy and proof of concept data in solid tumors with gene-edited allogeneic CAR T cells. Before joining Allogene, Arun held the position of Distinguished Scientist and Product Development Lead, Hematological Malignancies at Merck. There, he played a pivotal role in driving the approval of Pembrolizumab in lymphomas. Arun's expertise and insights have also led to his involvement on the scientific advisory boards of diagnostic companies. Arun's thought leadership is evident through his extensive publication record. He has authored over 40 peer-reviewed articles in esteemed journals such as Blood, Stem Cells, Journal of Clinical Oncology, and Nature Medicine. With his wealth of experience and expertise, Arun is poised to make significant contributions as the CMO at Replay, leading the way in driving innovation and success in the field of genomic medicine.

Laurent is a serial biotech entrepreneur, investor, and senior executive in the pharma/biotech industry. Laurent is co-founder & CEO of PriveBio Inc. a precision medicine biotech treating cardiometabolic diseases with a pipeline of first-in-class anti-fibroinflammatory and anti-obesity therapeutics. He’s also an Executive Partner with the Biotech VC fund, Apollo Health Ventures. He has contributed to the identification and development of seven novel medicines addressing unmet medical need across multiple disease areas administered to >300,000 patients and generating >$3B in annual sales. Laurent has led business and R&D functions in both pharma and biotech (US and EU), including founding CEO of Kymera Therapeutics (NASDAQ: KYMR), founder and CEO of Parthenon Therapeutics, Head of R&D with Pierre Fabre Pharmaceuticals, and positions of increasing leadership responsibilities on the business and science & clinical fronts at Pfizer, Merck, and Pieris (NASDAQ: PIRS) contributing to the advancement of 21 drug candidates (biologics and small molecules) into clinical development across multiple disease areas and modalities. He has also completed partnering transactions worth over $3B in deal size and raised > $300M. He studied chemistry (B.S. Honors) and molecular pharmacology (PhD) at Vanderbilt University and completed postdoctoral training at UNC/Chapel Hill and Duke University where he was the recipient of a prestigious American Heart Association Fellowship. He is Professor of the Practice at Northeastern University Center for Artificial Intelligence in Drug Discovery and Development (EAI) and on Vanderbilt Board of Visitors Executive Committee. He has co-authored over 80 papers and patents. Laurent serves on Ventus’ SAB and as an independent director on the boards of Naya Biosciences and Ilya Pharma.

Dr. Johan Baeck, the Chief. Medical Officer at Promontory Therapeutics, brings over 14 years of expertise in immuno-oncology clinical development. His career has spanned both smaller, emerging biotech firms and large pharmaceutical companies, including a notable nine-year tenure at Novartis. Specializing in treatments for liquid and solid tumors, Dr. Baeck’s extensive experience encompasses his fifth role in biotech, demonstrating his seasoned insight into drug development processes. His dual exposure to both dynamic biotech environments and structured big pharma settings equips him with a comprehensive understanding of oncology patient care and therapeutic innovation.

Eugenia Pankow is a crucial member of the Servier Pharmaceuticals Patient Advocacy and Engagement team. As the US Research & Development (R & D) Advocacy Lead, Ms Pankow assures that patient engagement in the research process meets the expectations of regulatory bodies, advocacy organizations and internal and external stakeholders. She works to enhance the clinical development process by engaging patients, caregivers, and advocacy groups. Ms Pankow plays an integral role in developing and maintaining advocacy group relations, and is committed to elevating the insights of patients, caregivers, and advocacy groups throughout the clinical development process. Ms Pankow started her career working for the NJ Child Protective Services agency advocating for abused and neglected children. Her time in child protective services led her to serve as the director of a NJ nonprofit adoption agency. She worked with children, birth parents and adoptive parents in building families and providing resources and services for them. Seeking another avenue to utilize her social work skills and nonprofit experience, Ms Pankow obtained a position with AbbVie as a patient advocate specializing in Crohn’s, Ulcerative Colitis, Psoriasis and Psoriatic Arthritis. She remained with AbbVie for five years before securing a position at Allergan on their newly established patient advocacy team. While at Allergan, she worked with her cross functional teams, patients and advocacy groups specializing in the areas of rare disease and gastroenterology. Being an advocate for those in need has been a common theme in Ms Pankow's career and throughout her life. Ms Pankow has dedicated her life to serving and supporting others throughout her career.

Michelle Ouellette is dedicated to creating patient partnerships for clinical development. In her current role she leads new initiatives that bring together stakeholders to advance the Syneos Health and Patient-Powered Medicine mission to harness the power of lived experience by researching and applying real world insights to drug development and delivery. Ms Ouellette has 15+ years of experience in health marketing communications including pharmaceuticals, spanning therapeutic areas and in both pre- and post-marketing. Ms Ouellette serves on the board of the White Coats Foundation, a global organization that aims to raise awareness about the role of clinical trials in advancing medical science and healthcare. Ms Ouellette enjoys yoga, travel and volunteer work with Cavalier Rescue USA.

Shawn Trutna is Senior Patient Engagement Lead at Syneos Health and is responsible for the strategizing, developing, and implementing patient and retention initiatives that pertain to strategic accounts at Syneos Health. Mr. Trutna has held previous positions in the last 17 years that have focused on research site recruitment optimization, digital outreach campaigns, HCP referring platforms, and connecting with patient advocacy organizations. He has a passion for problem solving and optimizing patient awareness initiatives in clinical research studies in multiple indications. Shawn earned a MS degree in Exercise Physiology from East Carolina University and a MS in Clinical Research and Development at Campbell University. In his spare time, Shawn enjoys spending time riding his bike with his MS Bike team members and listening to new music when his 9 year old son allows him to.

Wessam Sonbol is an entrepreneur, product strategist, and healthcare innovator focused on improving how clinical research engages patients and collects real-world data. He is the Founder and CEO of Delve Health, a technology and services company that helps pharmaceutical, biotechnology, and medical device organizations run more efficient clinical trials by improving patient compliance, retention, and data quality.

With more than two decades of experience in clinical research and digital health, Wessam has built solutions that combine patient-reported outcomes (eCOA/ePRO), wearable devices, digital biomarkers, and patient engagement services into unified research platforms. Under his leadership, Delve Health developed the Clinical StudyPal™ platform, designed to simplify study execution while enabling researchers to capture real-world evidence through connected sensors, digital assessments, and automated engagement workflows.

Wessam is particularly passionate about bridging the gap between clinical trials and real-world patient experiences. His work focuses on reducing operational burden for research sites while ensuring participants remain engaged throughout a study. By integrating digital technologies with human support models—such as Delve Health’s patient concierge services—he advocates for a more patient-centric approach to research.

Beyond product development, Wessam is an active voice in conversations around decentralized trials, digital endpoints, and the evolving role of wearable technology in clinical studies. He frequently shares insights on improving compliance, reducing vendor fragmentation, and accelerating evidence generation in modern research.

Through his work, Wessam continues to push the clinical research industry toward a future where technology, data, and patient engagement work together to generate more reliable evidence and bring better therapies to patients faster.